AKM DEFERASIROX FC, PHARMACOR DEFERASIROX FC (Pharmacor Pty Ltd)
Product name
AKM DEFERASIROX FC, PHARMACOR DEFERASIROX FC
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
147 (255 working days)
Active ingredients
deferasirox
Registration type
New generic medicine
Indication
The treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. AKM DEFERASIROX FC, PHARMACOR DEFERASIROX FC (tablet) is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective.
AKM DEFERASIROX FC, PHARMACOR DEFERASIROX FC is also indicated for the treatment of chronic iron overload in patients with nontransfusion-dependent thalassemia syndromes aged 10 years and older.